Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation
Biomolecules · 2024
DOI: 10.3390/biom14081043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Zixuan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Network Pharmacology, Molecular Docking Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Research Fund of Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
This study aims to explore the potential mechanisms of esculin in the treatment of renal cell carcinoma (RCC).
Methods
We employed network pharmacology to predict the potential mechanisms and targets of esculin in RCC. Molecular docking techniques were then employed to validate the predicted targets. Additionally, a series of in vitro experiments were conducted to verify the anticancer effects of esculin on RCC cells, including the CCK-8 assay, EdU assay, wound healing assay, apoptosis assay, and Western blot.
Results
Network pharmacology and molecular docking results identified GAPDH, TNF, GSK3B, CCND1, MCL1, IL2, and CDK2 as core targets. GO and KEGG analyses suggested that esculin may influence apoptotic processes and target the PI3K/Akt pathway in RCC. Furthermore, the CCK-8 assay demonstrated that esculin inhibited RCC cell viability. Microscopic observations revealed that following esculin treatment, there was an increase in cell crumpling, a reduction in cell density, and an accumulation of floating dead cells. Additionally, with increasing esculin concentrations, the proportion of EdU-positive cells decreased, the wound closure ratio decreased, the proportion of PI-positive cells increased, the expression levels of BAX and cleaved-caspase-3 proteins increased, and the expression level of Bcl2 protein decreased. These findings suggested that esculin inhibits the proliferation and migration of RCC cells while promoting apoptosis. Moreover, esculin was found to target GAPDH and inhibit the PI3K/Akt pathway.
Conclusions
This study is the first to elucidate the therapeutic effects of esculin on RCC cells. The results provide evidence supporting the clinical application of esculin and introduce a promising new candidate for RCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
- Department of Traditional Chinese Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
- College of Medicine, Yanbian University, Yanji 133002, China.
- Department of Anesthesiology and Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
- Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
ORCID-Profile: Zixuan Chen, Sheng Cheng
Förderung
- the National Natural Science Foundation of China
- Research Fund of Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z., Wang, C., Cai, Y., Xu, A., Han, C., Tong, Y., Cheng, S., & Liu, M. (2024). Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation. Biomolecules. https://doi.org/10.3390/biom14081043
Vancouver
Chen Z, Wang C, Cai Y, Xu A, Han C, Tong Y, et al. Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation. Biomolecules. 2024. doi:10.3390/biom14081043
BibTeX
@article{Chen2024,
author = {Chen, Zixuan and Wang, Cunzhou and Cai, Yuesong and Xu, An and Han, Chengtao and Tong, Yanjun and Cheng, Sheng and Liu, Min},
title = {Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14081043}
}
EUVIMED